Vection Technologies (ASX:VR1) has received $1.2 million in non-repayable, non-dilutive government funding across four R&D programs spanning artificial intelligence, extended reality and digital health.

💰 Government funding: The $1.2 million in cash will support Vection Technologies’ existing product roadmap, expand collaboration opportunities and strengthen working capital without dilution to shareholders.
🩺 Digital health development: The AI-powered Digital Health Rehabilitation (OMNIREHAB) program is developing an AI-powered remote rehabilitation platform combining motion capture and Extended Reality (XR) for home-based cognitive and physical rehabilitation.
🤖 Broader technology pipeline: The funding also supports projects focused on inclusive AI and sign-language translation, cultural and museum AI, and immersive heritage visualisation, with research partners including University College London (UCL), the National Research Council of Italy (CNR) and several Italian universities.

"The technologies and capabilities we are developing will be integrated into Algho AI and IntegratedXR, while other activities will generate standalone intellectual property." – Gianmarco Biagi, Vection Technologies Managing Director and Executive Chairman

Austco Healthcare (ASX:AHC) strengthens its direct presence in the Australian healthcare market, agreeing to acquire long-standing South Australian reseller Medical Communications Systems (MCS) for approximately $2.88 million.

🏥 Strategic acquisition: Austco will acquire 100% of MCS, bringing its South Australian nurse call reseller in-house and strengthening direct customer relationships and service delivery in the state.
💰 Earnings accretive: The transaction comprises approximately $2.24 million in upfront cash and an estimated $0.64 million performance-based earnout. On a full-year basis, MCS is expected to contribute approximately $1.88 million of incremental revenue and $0.82 million of EBITDA.
📈 Proven M&A strategy: The acquisition follows Austco’s previous reseller acquisitions of Teknocorp, Amentco and G&S Technologies. MCS has been an Austco-certified reseller since 2011, with its 12 staff expected to remain with the business.

“This acquisition follows the same disciplined model as our last three acquisitions: strengthening our direct sales capability, deepening our customer relationships and retaining experienced local people.” – Clayton Astles, Austco Healthcare CEO

Braveheart Bio (NASDAQ: BRVE) just raised $440 million to list on the Nasdaq. It was founded two years ago, and its primary drug treats a heart condition where the muscle thickens and struggles to pump.

Braveheart didn`t invent the drug, they licensed it from a pharmaceutical company in China, every clinical trial so far was designed and run entirely by that Chinese company. Braveheart wasn`t involved and doesn`t manufacture the drug. What Braveheart bought was the exclusive right to seek FDA approval and sell the drug everywhere, except Greater China.

There have been more than one hundred similar licensing deals since the start of last year. Increasingly, cutting-edge medicines are invented in China and sold to you by American biotechs.

#biotech #stocks #nasdaq #IPO #fintok

Patrys (ASX:PAB) is advancing its lead drug candidate, RLS-2202, towards its first clinical trial in humans. During the June quarter, Patrys appointed a specialist clinical trial site and contract research organisation, progressed its trial protocol and submitted its ethics application. The company is now targeting first participant dosing in Q3 2026, subject to the required approvals. Patrys CEO Dr Samantha South joins The Stock Network`s Lel Smits to discuss RLS-2202, the company`s path into the clinic and what investors can expect next.

⚕️ Getting RLS-2202 into the clinic
🔬 What RLS-2202 could do
🚀 What`s next for Patrys

Who is winning the weight loss boom? It`s not the company that makes Ozempic. It`s Eli Lilly And Co (NYSE:LLY), which makes Ozempic`s biggest rival, Mounjaro.

Mounjaro and its sister product were about two-thirds of everything Lilly sold in the second quarter with total revenue rising 48% to was $23 billion over the last year.

Here`s the strange part - Lilly`s prices went down, while it sold 60 per cent more and charged 13 per cent less. That`s what a boom actually looks like: not charging more but reaching more people.

#money #health #stocks #GLP1 #weightloss

Osteopore (ASX:OSX) has expanded its orthopaedic bone reconstruction business into the Middle East after signing a three-year distribution agreement with Al-Umnia Medical covering five Gulf Cooperation Council (GCC) markets.

🦴 Regional expansion: The agreement covers Saudi Arabia, the United Arab Emirates, Oman, Qatar and Bahrain, with Osteopore and Al-Umnia now progressing product registrations across the five countries.
🌍 Large addressable market: The GCC orthopaedic devices market was valued at approximately US$897.5 million in 2025 and is forecast to reach US$1.55 billion by 2034, according to cited market research.
🤝 Established partner: Dubai-based Al-Umnia has grown from a four-person team in 2009 to more than 70 employees, with a focus on medical technology partnerships, clinical education, training and support across the GCC.

"Our orthopaedics bone reconstruction product line is now progressing to the next phase of commercialisation – beyond South East Asia to the Middle East." – Dr Yujing Lim, Osteopore CEO

ADHD rates are soaring and one ASX company founded by Princeton neuroscientists, wants to change that. BlinkLab’s (ASX:BB1) smartphone app used the phone`s camera to measure involuntary responses like blinking.

A recent European study showed it correctly identified 82 per cent of the children who had an ADHD diagnosis, and correctly cleared 83 per cent of those who didn`t.

It`s early research but if you`ve ever waited months for a specialist appointment, you know why someone`s trying. The idea isn`t to replace the specialist. It`s to work out who needs one first.

#finance #health #stocks #ADHD #fintok

What`s a lockup and why does it matter to SpaceX Space Exploration Technologies Corp. (SPCX) shareholders? When a company lists, early investors such as founders, staff and venture funds agree to hold their shares for a set period. The reason is simple. Nobody would want to invest in a company if insiders could cash out the next morning.

SpaceX listed in June, in the biggest IPO ever. Now the first lockup period is ending, and over 900 million more shares can be sold by those early holders. If enough of them decide to cash out, this could put even more pressure on SpaceX`s share price. It’s worth knowing whenever you see a hot new listing. There’s a second date, months later, that nobody puts in the headline.

#fintok #elonmusk #spaceX #money #investing